Locate your nearest distributor

Location:
Type:
Text search:
Username:
Password:
Forgot password?

News Archive

Biohit Acetium® lozenge is a highly effective means to stop smoking

22.05.2017 09:30

Biohit Acetium® lozenge is a highly effective means to stop smoking – results confirmed in a new large-scale trial. Read more ...

Lea Paloheimo appointed Biohit Oyj’s R&D and production director

04.05.2017 10:00

Lea Paloheimo, PhD (clinical biochemistry), has been appointed Biohit Oyj’s R&D and production director. Lea Paloheimo has been a member of the Biohit Oyj’s management team since 2006. Read more

Constitutive meeting of Biohit Oyj’s Board of Directors

27.04.2017 09:30

Biohit Oyj Other information disclosed according to the rules of the Exchange April 27, 2017 at 9:30 am local time (EEST) Biohit Oyj’s Board of Directors has in its meeting yesterday elected Mr Osmo Suovaniemi as the Chairman of the Board of Directors. Read more

Decisions of the Annual General Meeting of Biohit Oyj

26.04.2017 19:30

Biohit Oyj Decisions of general meeting April 26, 2017 at 7:30 pm local time (EEST) The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday April 26, 2017 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2016. Read more...

Biohit Oyj B-shares subscribed with Stock Options I 2013 B

20.04.2017 09:30

Biohit Oyj Total number of voting rights and capital April 20, 2017 at 9:30 am (EEST) A total number of 21 858 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 B between 2 December 2016 and 9 March 2017. These shares have been entered into the trade register on April 20, 2017, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ Helsinki as of April 21, 2017 together with the existing B-shares. Read more...

NOTICE OF BIOHIT OYJ’S ANNUAL GENERAL MEETING

03.04.2017 09:30

Biohit Oyj Notice to general meeting April 3, 2017 at 9:30 am local time (EEST) Biohit Oyj shareholders are invited to attend the company’s Annual General Meeting to be held on Wednesday, April 26, 2017 starting at 5:00 pm at Pörssitalo. The address is Fabianinkatu 14, 00100 Helsinki. The reception of shareholders registered for the meeting and the distribution of voting slips will commence at 4:00 pm. Read more...

Publication of Biohit Oyj Annual Report 2016

23.03.2017 09:30

Biohit Oyj Annual Financial Report March 23, 2017 at 9:30 am local time (EET) Biohit Oyj’s Annual Report 2016 is published today in PDF format. Read more

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2016

20.02.2017 09:30

Biohit Oyj Financial Statement Release, 20 February 2017 at 9:30 am local time (EET). Read more

Biohit Oyj’s CEO Semi Korpela will return to work on 20.2.2017

20.02.2017 09:29

Biohit Oyj Stock Exchange Release February 20, 2017 9:29 am local time (EEST) Biohit Oyj announced on January 5, 2017 that CEO Semi Korpela would take a sick leave of approximately one month, related to pneumonia and recovery from it. Korpela has recovered from his illness and will return to work on 20.2.2017. Read more

Biohit Oyj CEO Semi Korpela takes sick leave

05.01.2017 13:00

Biohit Oyj Stock Exchange Release January 5, 2017 at 1:00 pm local time (EEST) Starting from January 5, 2017 Biohit Oyj´s CEO Semi Korpela will take a sick leave of approximately one month related to pneumonia. During Semi Korpela´s sick leave, his deputy will be Biohit Oyj`s CFO Niklas Nordström. Read more

Ownership arrangement in Biohit Oyj’s Chinese Joint Venture – 2017 operating result expected to be positive

02.01.2017 09:30

Biohit Oyj Stock Exchange Release January 2, 2017 at 09:30 am local time (EEST) Biohit Oyj and Anhui Wisdom-Win Investment Co. Ltd have signed a resolution authorised by shareholders of Biohit HealthCare (Hefei) Co. Ltd, a joint venture operating in Hefei, China, concerning reduction of the joint venture share capital for an amount equal to Biohit Oyj’s shareholding. Biohit Oyj owns 40% of the company, and the agreement is for reduction of the entire share capital. As a result of the transaction Biohit Oyj estimates its operating result to turn clearly positive for 2017. Re...